Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25
Chardan Capital analyst Gautam Chukka maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $26 to $25.
Stocks · News reference
4D Molecular Therapeutics Announces First Patients Enrolled In Phase 3 Trial Of 4D-150 In Diabetic Macular Edema; 2-Year Data Show 61% Fewer Injections
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33
B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.
8-K filing — 4D Molecular Therapeutics, Inc. (FDMT)
Filed: 2026-09-28 AccNo: 0001193125-26-403424 Size: 150 KB Item 8.01: Other Events